Protalix Biotherapeutics, Inc. (PLX)

Protalix's stock experienced a significant one-day decline of 22.5% on October 17, 2025. The company's Q3 2025 earnings were reported on November 13, 2025, missing EPS forecasts by 57.14%, leading to a 13.55% plunge in the stock price during premarket trading, and investor sentiment deteriorated around November 19, 2025, as the stock fell 17%. Protalix Biotherapeutics and Secarna Pharmaceuticals announced a collaboration and option agreement on December 17, 2025. The company's President reportedly bought US$101k worth of stock on December 24, 2025. Protalix BioTherapeutics issued a letter to stockholders on January 5, 2026. Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. received a positive CHMP opinion for an additional dosing regimen of 2mg/kg body weight every-four-weeks for Elfabrio in the EU on January 30, 2026, contributing to an improvement in investor sentiment, with the stock rising 19% around January 9, 2026, and 26% around February 2, 2026. Consensus EPS estimates for PLX were downgraded on February 5, 2026. Historically, September has shown increased volatility for the stock, while the fourth quarter, particularly November and December, often exhibits stronger performance.

The provided search results do not contain specific information regarding demand seasonality for Protalix BioTherapeutics' products and services.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based expression system. The company has received FDA approval for a protein produced through this method. Protalix's major approved products include Elelyso for Gaucher disease, with Pfizer holding worldwide rights excluding Brazil, and Elfabrio for Fabry disease, developed and commercialized in partnership with Chiesi Farmaceutici S.p.A. The company's clinical development pipeline includes PRX-115 for severe gout and PRX-119 for NETs-related diseases.

Protalix BioTherapeutics is headquartered in Karmiel, Israel, and has operations in the United States, with a corporate address in Hackensack, New Jersey. The company's commercial reach extends through partnerships, with Pfizer marketing Elelyso globally (excluding Brazil) and Chiesi Farmaceutici S.p.A. handling Elfabrio in the United States and the European Union. Protalix also operates in other countries, including Australia, Canada, Brazil, Russia, and Turkey.

Protalix BioTherapeutics has generally maintained a positive outlook from analysts, with a consensus "Buy" rating. The company's MarketRank™ score indicates it performs better than 62% of companies in the medical sector. However, the company's Q3 2025 EPS missed analyst expectations, leading to a stock price drop and a deterioration of investor sentiment in November 2025. There have been reports of Chiesi reducing milestone payments by $25 million, and concerns have been raised about a continued lack of market traction for Elfabrio. Potential operational disruptions due to the ongoing conflict in Israel have also been cited as a risk. Positive developments such as the positive CHMP opinion for Elfabrio in the EU and a collaboration agreement with Secarna Pharmaceuticals contribute to a favorable reputation.

Protalix BioTherapeutics, Inc. has a diverse ownership structure, including institutional investors, private equity, and retail shareholders. As of March 6, 2026, there were 97 institutional owners holding a total of 15,112,034 shares, including major holders such as BlackRock, Inc., Opaleye Management Inc., and Renaissance Technologies Llc. Insider ownership accounts for approximately 9.49% of total shares outstanding, with significant insider holders as of February 19, 2026, including TenPercentOwner Pharma Technologies Ltd. Dexcel, President and CEO Dror Bashan, and Sr. VP and CFO Eyal Rubin.